Innovations for immune therapy development, biomarker discovery and proteomics
JPT’s proprietary technologies and corresponding product portfolio help to advance research efforts in the development of new immunotherapies and vaccine strategies against infectious and autoimmune diseases as well as allergies and cancer. Our high-quality peptide libraries, peptide arrays, peptide pools and GxP peptides enable the development of novel individualized therapeutic approaches, as well as epitope-resolved clinical immune monitoring. For the first time, deep epitope-based analysis and correlation of the cellular and humoral immune responses of diverse patient populations is feasible. This provides a basis for stratifying patient groups and developing novel immune diagnostics and therapeutic approaches. In a similar way, JPT’s peptide-based platforms permit the discovery and qualification of B- and T-cell epitopes, neoepitopes as well as the absolute and multiplexed quantitation of protein expression levels targeting entire proteomes.